Amarin Provides Pricing & Reimbursement Updates for VAZKEPA (icosapent ethyl) in The Netherlands and Italy - Seite 2
“In Italy, cardiovascular diseases are responsible for 35.8% of all deaths, exceeding 230,000 cases annually and represent the leading cause of death and hospitalization2,” added Holt. “While we are disappointed with today’s decision, we continue to stand behind the proven therapeutic benefit of our product and we will continue our efforts to ensure patients across Italy have access to VAZKEPA to reduce their cardiovascular risk.”
Amarin continues to advance its pricing and reimbursement discussions in a number of other European markets to drive patient access across the region and will share updates as these become available.
About Amarin
Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. We are committed to increasing the scientific understanding of the cardiovascular risk
that persists beyond traditional therapies and advancing the treatment of that risk for patients worldwide. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland,
Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world.
Lesen Sie auch
Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of U.S. securities laws, including, but not limited to, expectations regarding the Dutch approval of VAZKEPA for national
reimbursement and the market potential in that territory; the negative decision on pricing in Italy, and Amarin’s plan to continue seeking pricing and reimbursement in that country; Amarin’s
continued efforts to advance its pricing and reimbursement discussions in a number of other European markets; and beliefs about the overall world-wide market potential and success of
VASCEPA/VAZKEPA generally. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. A list and description of these risks, uncertainties and
other risks associated with an investment in Amarin can be found in Amarin’s filings with the U.S. Securities and Exchange Commission, including Amarin’s annual report on Form 10-K for the year
ended December 31, 2022. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Amarin
undertakes no obligation to update or revise the information contained in its forward-looking statements, whether as a result of new information, future events or circumstances or otherwise.
Amarin’s forward-looking statements do not reflect the potential impact of significant transactions the company may enter into, such as mergers, acquisitions, dispositions, joint ventures or any
material agreements that Amarin may enter into, amend or terminate.